Our results demonstrate that HMN-214 significantly inhibits NB spheroid tumor growth in a dose-dependent manner, in contrast to controls in both MYCN-amplified and MYCN-non-amplified spheroid tumors (Figure 6A and Figure 7A). Here, MYCN is linked to neuroblastoma.